Clinical Trials Logo

Leukemia, Myeloid, Chronic clinical trials

View clinical trials related to Leukemia, Myeloid, Chronic.

Filter by:

NCT ID: NCT00167167 Completed - AML Clinical Trials

Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia

Start date: December 1995
Phase: N/A
Study type: Interventional

In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.

NCT ID: NCT00067002 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Randomized Double Cord Blood Transplant Study

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if combining cord blood units to make the cells "take" faster in recipients will help to improve the results of cord blood transplants.

NCT ID: NCT00050531 Completed - Clinical trials for Leukemia, Myeloid, Chronic

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Start date: April 2003
Phase: Phase 3
Study type: Interventional

The goal of this clinical research study is to learn if giving PEG-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec (imatinib mesylate) is more effective in treating CML in chronic phase than therapy with imatinib mesylate alone.

NCT ID: NCT00040105 Completed - Clinical trials for Leukemia, Myeloid, Chronic

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Start date: October 2002
Phase: Phase 1
Study type: Interventional

The goal of this clinical research study is to find the highest safe dose of the drugs ZarnestraTM (R115777) and Gleevec (imatinib mesylate) that can be given in combination for the treatment of chronic myelogenous leukemia (CML) in chronic phase. The effect of this combination on the leukemia will also be studied.

NCT ID: NCT00034684 Completed - Leukemia Clinical Trials

Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

Start date: July 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.

NCT ID: NCT00027144 Completed - Clinical trials for Leukemia,Myeloid, Chronic

Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic Phase

Start date: December 2000
Phase: Phase 1
Study type: Interventional

Description: The trial is designed to determine the response of the immune system of patients with CML to a vaccine made from their own tumor. Researchers believe that this particular vaccine, which is made from purified heat shock proteins taken from each patient's tumor, alerts the body's immune system to recognize and attack invading cancer. To be considered potentially eligible for this study you must have CML in the chronic phase. Length/Duration: Vaccinations will be administered weekly for eight weeks. One clinic follow up visit will be scheduled two weeks after the final vaccination.